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Abstract: Current national and international asthma guidelines recommend treatment of children 
with asthma towards achieving and maintaining asthma control. These guidelines provide more 
stringent recommendations to increase therapy for patients with uncontrolled asthma in order to 
reduce asthma-related morbidity and mortality. Newer combination agents such as budesonide 
and formoterol have been shown to be safe and effective in treatment of asthma in children. Use 
of long-term controller agents like this in combination with improved compliance and treatment 
of co-morbid conditions have been successful in this endeavor. This review discusses control of 
pediatric asthma with focus on the use of budesonide in combination with formoterol.
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Introduction
National and international asthma treatment guidelines have recently focused on 
control of asthma. These guidelines provide more stringent recommendations to 
increase therapy for patients with uncontrolled asthma in order to reduce asthma 
related morbidity and mortality. Further, they recommend different combinations 
of controllers for long term treatment of persistent asthma including addition of 
long-acting β2-agonists (LABA) to inhaled corticosteroid (ICS) therapy.1,2 This 
review discusses control of pediatric asthma with focus on the use of budesonide in 
combination with formoterol.
Diagnosis of asthma in children
Before long term controller medication can be initiated, the diagnosis of asthma 
must be made. Many studies show that asthma is under diagnosed particularly in 
children.3–5 Asthma is a chronic inflammatory disease of the airways characterized 
by episodic and reversible airflow obstruction. A clinical diagnosis of asthma is 
often prompted by symptoms of cough, shortness of breath, chest tightness, or 
wheezing. Spirometry is the recommended method of objectively measuring airflow 
obstruction and reversibility. Diagnosis of asthma is supported by reversible airflow 
obstruction as measured by forced expiratory volume at one second (FEV1) by 
more than 12% after bronchodilator therapy.6,7 There is no single diagnostic test 
for asthma, but careful review of symptoms along with physical examination and 
objective measurements of lung function can guide the clinician toward diagnosis. 
A detailed discussion on the differential diagnosis of asthma is beyond the scope 
of this review.Therapeutics and Clinical Risk Management 2010:6 66
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The diagnosis of asthma in younger children often 
presents a challenge for clinicians because episodic wheezing 
and cough are also common in children who do not have 
asthma. More than 50% of children in the United States 
and the United Kingdom wheeze in their first year of life.8 
The diagnosis of asthma is further complicated by the dif-
ficulty in obtaining objective measurements of lung function 
in children aged less than five years, the lack of definitive 
biomarkers, and the difficulty in discerning among the dif-
ferent asthma phenotypes.9–11
Castro-Rodriguez and colleagues developed the Asthma 
Predictive Index (API),12 a practical tool that helps clini-
cians identify children who are more likely to have asthma. 
This simple clinical index based on the presence of wheeze 
before the age of three, and the presence of one major risk 
factor (parental history of asthma or a personal history of 
atopic dermatitis) or two of three minor risk factors (allergic 
rhinitis, wheezing apart from colds, and eosinophilia), has 
been shown to predict the presence of asthma in later child-
hood. The API has a positive predictive value of 76% and a 
negative predictive value of 95% (Figure 1).
Asthma control in children
Currently most asthma guidelines measure asthma control 
using two domains consisting of 1) present asthma 
symptoms and lung function and 2) history of past asthma 
exacerbations.1,2 In the 2007 National Asthma Education 
Prevention Program Expert Review Panel 3 (NAEPP ERP 3) 
guidelines, assessment of a combination of current asthma 
symptoms (such as frequency of day and night symptoms), 
lung function, and asthma survey instruments such as the 
Asthma Control Test (ACT) are used to measure patient’s 
current impairment due to asthma. The number of prior 
asthma exacerbations requiring systemic steroid rescue is 
used to measure patient’s risk (Figure 2). Impairment and 
risk are then used to determine the level of patient’s asthma 
control. Long term asthma control reduces asthma associ-
ated impairment and is believed to result in reduced risk of 
exacerbations.13 We previously demonstrated that inner city 
asthmatic children who maintained a high degree of asthma 
control over the period of a year had a significantly lower 
risk of asthma exacerbations and emergency department 
visits/hospitalizations compared to similar children who had 
poor asthma control (Figure 3).14
Previous asthma guidelines recommended classification of 
asthma severity upon initial assessment prior to controller treat-
ment. This was an attempt to determine the baseline “controller 
naïve” asthma severity in patients and the level of controller 
therapy required.1,2 A recent update of those guidelines still 
recommends baseline classification of severity, but only as 
an initial starting reference point. Many patients initially seen 
by providers are not controller naïve and recent studies have 
demonstrated that asthma disease activity may vary over time 
and deviate significantly from the initial baseline classification. 
Patients initially classified with intermittent asthma may 
experience severe exacerbations at distal time points.15,16 
Four episodes of wheezing in one year
+
Major criteria Minor criteria
Parent with physician-diagnosed asthma Wheezing apart from colds
Physician-diagnosed eczema Physician-diagnosed allergic rhinitis
Eosinophilia (>4%)
Figure 1 Asthma Predictive index. History of early wheezing in a child with at least one major criteria or two minor criteria had a positive predictive index of 76% in children. 
Copyright © 2008,   American Thoracic Society. Adapted from Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD.   A clinical index to define risk of asthma in young 
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in these patients. Reasons for this include poor patient 
understanding of the disease, complexity of treatment, access 
to care and medications, and socioeconomic factors.21,22
Control of co-morbid conditions including allergic rhinitis, 
sinusitis, and gastroesophageal reflux disease (GERD) are 
important in achieving asthma control in children. This often 
allows asthma control using lower doses of controller agents, 
reducing risk of side effects. Pathology of the upper airway 
is believed to adversely impact the lower airways of asth-
matics via mechanisms that are not completely understood. 
However, neuronal and inflammatory pathways have been 
implicated.23,24 Treatment of the upper airway with intranasal 
steroids, antihistamines, and leukotriene receptor antagonists 
(LTRA) have been shown to improve asthma control.25–27 
Control of GERD with proton pump inhibitors, H2 blockers 
and surgery has also been shown to improve asthma symptoms 
and reduce doses of controller agents required.28,29
Controller agents recommended 
for long-term asthma control  
in children
inhaled corticosteroids
Inhaled corticosteroids (ICS) remain the cornerstone of asthma 
treatment for children of all ages.1,2 They are the most potent and 
effective anti-inflammatory medication currently available. 
For instance, it is well described that young children may have 
relatively mild asthma symptoms (impairment) throughout 
the year, but may have severe exacerbations during periods of 
viral infections (risk).17,18 Congruent with these observations, 
guidelines stress that ongoing monitoring of disease activity 
is essential to maintaining asthma control wherein asthma 
control is the measurement used during real time assessment 
of asthmatics at each provider encounter. Dynamic pharma-
cologic therapy using a stepwise approach is recommended 
with “step up” of controller agents when control is poor and 
“step down” of medications when control is maintained for 
extended periods of time (Figure 4).
Compliance and treatment  
of co-morbid conditions
Compliance and treatment of co-morbid conditions play 
major roles in achievement of asthma control in children. 
Asthma is a chronic disease and long term treatment is 
imperative to reduce risk of morbidity and mortality. Consis-
tent with findings of other investigators, we have shown that 
compliance is a major independent variable that contributes 
towards maintaining asthma control in inner city asthmatic 
children once initial disease control was achieved.19,20 
Long-term compliance is unfortunately suboptimal in many 
asthmatic children, which contributes to poor asthma control 
Classification of asthma control
(5–11 years of age)
Well controlled Not well 
controlled
Very poorly 
controlled
Impairment Symptoms 2 days/week >2 days/week Daily
Night-time 
awakenings
1x/month >2x/month >2x/week
Interference with
normal activity
None Some limitation Extremely limited
SABA use for 
symptom control
>2 days/week Several times/day
Lung function:
− FEV1 or peak  
flow
− FEV1/FVC
>80% 
predicted/personal 
best
>80%
60%–80%
predicted/personal 
best
75%–80%
<60% 
predicted/personal 
best
<75%
Risk Exacerbations 
requiring oral 
systemic 
corticosteroids
0–1/year ≥2/year
≤
≤
≤ ≤2 days/week
Figure 2 Assessing asthma control in children aged 5–11 years. Refer to NAePP guidelines for other age groups.   Adapted from National   Asthma education and 
Prevention Program. Guidelines for the Diagnosis and Management of   Asthma: expert Panel Report 3. Bethesda, MD: National institutes of Health, National Heart, Lung 
and Blood institute; 2007.
Abbreviations: Fev1, forced expiratory volume in one second; FvC, forced vital capacity; SABA, short-acting β2-agonists.Therapeutics and Clinical Risk Management 2010:6 68
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Corticosteroids block late-phase reaction to allergens, reduce 
airway hyperresponsiveness, and inhibit inflammatory cell 
migration and activation.30–32 ICS reduce asthma symptoms, 
improve quality of live, reduce frequency and severity of 
exacerbations, and reduce asthma mortality.33–35 The potential 
but small risk of adverse effects from ICS is well balanced 
by their efficacy. Local adverse effects include oropharyngeal 
candidiasis and dysphonia. Systemic adverse effects of long-
term treatment with high doses of ICS include easy bruising,36 
adrenal suppression,37,38 and decreased bone mineral density.39 
The risk of systemic adverse effects depends upon its dose 
and potency. Low and medium doses of ICS appear to 
have no serious adverse effects on bone mineral density in 
children.40 In addition, low and medium dose ICS have no 
significant effects on the incidence of subcapsular cataracts 
or glaucoma.41 Perhaps the more significant adverse effect of 
ICS is growth velocity reduction in children. The available 
cumulative data suggest that even low-dose ICS have the 
potential for decreasing growth velocity, although the effects 
are small.42,43 Despite a small reduction in growth velocity, 
studies of early intervention with low- or medium-dose ICS 
showed significantly improved asthma outcomes.33,44
The efficacy and tolerability of the ICS, budesonide, is 
well established in the treatment of pediatric asthma.45,46 One 
of the largest and longest studies demonstrating the benefit 
of ICS in pediatric patients with asthma is the Childhood 
Asthma Management Program (CAMP).47 1,041 children 
aged from 5 to 12 years with mild-to-moderate asthma 
were randomly assigned to receive either 1) budesonide, 
2) nedocromil, or 3) placebo and were followed for four to six 
years (mean 4.3 years) . Children given budesonide experi-
enced fewer hospitalizations and urgent care visits, decreased 
symptoms, decreased need for albuterol rescue therapy, and 
fewer episodes of acute asthma requiring oral prednisone. 
However, neither budesonide nor nedocromil was better 
than placebo in terms of improving lung function in the 
long term. These findings suggest that continuous, long-
term ICS treatment of children did not prevent deficits in 
lung function and did not alter the rate of progression of 
asthma. Side effects of budesonide included small, transient 
reduction in growth velocity. The mean increase in height 
in the budesonide group was 1.1 cm less than the mean 
increase in the placebo group. The difference between the 
budesonide and placebo groups in the rate of growth was 
evident primarily within the first year of treatment.
The CAMP investigators speculated that ICS did not affect 
the natural course of asthma because treatment did not begin 
early enough. The Prevention in Early Asthma in Kids study 
(PEAK) attempted to address this issue. The PEAK study was 
a multicenter, double-blind, randomized, placebo-controlled 
trial that investigated whether daily ICS could prevent the 
development of chronic asthma. 285 children aged two or 
three years with a positive asthma predictive index were 
randomized to receive either fluticasone propionate (88 µg 
twice daily) or masked placebo for two years, followed by a 
one-year period of observation without study medications.42 
During the treatment period, the children who received ICS 
had a greater proportion of episode-free days, a lower rate 
of asthma exacerbations, and decreased supplementary use 
of controller medications. However, during the observation 
period, no significant differences were seen between the 
two groups in the proportion of episode-free days, the number 
of exacerbations, or lung function. Therefore, in preschool 
children at high risk for asthma, two years of ICS therapy 
did not change the development of asthma symptoms or lung 
function during the third, treatment-free year. Congruent with 
findings from the CAMP study, the children who received 
ICS had a mean increase in height 1.1 cm less than the mean 
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Figure 3 Degree of asthma control during year 1 was associated with probability of asthma exacerbation during year 2 in inner city children with asthma living in Los Angeles. 
Degree of asthma control was defined as the percentage of clinic visits during year 1 when asthma was rated as controlled based upon NAEPP ERP 2 asthma guidelines. 
Copyright © 2008, elsevier.    Adapted from Kwong KY, Morphew T, Scott L, Guterman J, Jones CA.   Asthma control and future asthma-related morbidity in inner-city asthmatic 
children. Ann Allergy Asthma Immunol. 2008;101(2):144–152.Therapeutics and Clinical Risk Management 2010:6 69
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increase in the placebo group at 24 months. However, by the 
end of the trial, the height increase was only 0.7 cm less.
The START study evaluated the safety and tolerability 
of long-term treatment of both children and adults who have 
mild persistent asthma.48 17.8 % and 27.8% of the patients in 
this study were aged 11–17 and 5–10 years, respectively. In 
the first three years of the START study, patients with mild 
persistent asthma who received low-dose daily budesonide 
had a reduction in their risk of a first severe asthma-related 
event by 44% compared to similar patients given placebo. 
Thus budesonide significantly reduced the overall risk 
of experiencing a severe asthma-related event in these 
pediatric patients. Similar to the CAMP study, children given 
budesonide compared to those receiving placebo experienced 
small reductions in growth velocity. However, low-dose daily 
budesonide was associated with significantly less effect on 
growth than with previously reported studies with high-dose 
budesonide.
Step 1
Preferred:
SABA prn
Step 2
Preferred:
Low-dose
ICS
Alternative:
Cromolyn,
LTRA,
Nedocromil 
or 
Theophylline
Step 3
Preferred:
EITHER: 
Low-dose
ICS + either
LABA, 
LTRA, or 
Theophylline 
OR
Medium-dose
ICS
Step 5
Preferred:
High-dose
ICS + LABA 
Alternative:
High-dose
ICS + either 
LTRA or 
Theophylline
Step 6
Preferred:
High-dose
ICS + LABA 
+ oral 
systemic 
corticosteroid
Alternative: 
High-dose
ICS + either 
LTRA or 
Theophylline 
+
Oral systemic 
corticosteroid
Step 4
Preferred:
Medium-dose
ICS + LABA
Alternative:
Medium-dose
ICS + either
LTRA or 
Theophylline
Intermittent 
asthma
Persistent asthma
Children aged 5−11 years
Figure 4 Stepwise Approach for managing asthma in children aged 5–11 years. Refer to NAePP guidelines for other age groups. Adapted from National Asthma education 
and Prevention Program. Guidelines for the Diagnosis and Management of   Asthma: expert Panel Report 3. Bethesda, MD: National institutes of Health, National Heart, Lung 
and Blood institute; 2007.
Abbreviations: iCS, inhaled corticosteroids; LABA, long-acting β2-agonists; LTRA, leukotriene receptor agonists; SABA, short-acting β2-agonists.Therapeutics and Clinical Risk Management 2010:6 70
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A long-term placebo-controlled study by Agertoft and 
colleagues involving 211 children who received long-term 
treatment with budesonide (mean duration 9.2 years) reported 
no adverse effects on final height.49 The mean daily dose of 
budesonide was 412 µg (range, 110 to 877) and the mean 
cumulative dose of budesonide was 1.35 g (range, 0.41 to 
3.99). Growth rates were significantly reduced during the 
first years of budesonide treatment; however, these changes 
in early growth rate were not significantly associated with 
reductions in predicted final adult height. Other studies using 
long-term treatment with ICS show similar catch-up growth 
after the initial period of administration.50–53
Taken together, these studies demonstrate that ICS 
significantly improve symptoms, reduce impairment, and 
reduce the likelihood of asthma-associated morbidity 
in children with asthma. The significant benefit of this 
agent is balanced with the risk of linear growth reduction 
especially during initial periods of use which may be caught 
up over time.
Combination therapy in children
NAEPP EPR 3 recommend combination therapy for the 
majority of children with moderate to persistent asthma.15 The 
most popular combinations are the use of ICS in combination 
with LABA and ICS in combination with LTRAs.
inhaled corticosteroids in combination 
with long-acting β2-agonist
Numerous studies have established that the addition of 
LABA to ICS in adults is more effective at controlling 
symptoms, improving lung function, and reducing asthma 
exacerbations than doubling the dose of ICS. In the Formoterol 
and Corticosteroids Establishing Therapy (FACET) study, 
Pauwels and colleagues reported that in adult patients with 
moderate asthma, the addition of formoterol to low or 
moderate doses of budesonide reduced the frequency of asthma 
exacerbations, improved symptoms, and lung function.54 
In this double-blind parallel group study, 852 patients were 
randomly assigned to receive one of the following treatments 
for one year: 1) budesonide 100 µg bid, 2) budesonide/
formoterol 100 µg/12 µg bid, 3) budesonide 400 µg bid, or 4) 
budesonide/formoterol 400 µg/12 µg bid. A post-hoc analysis 
of the FACET study confirmed that the addition of formoterol 
to low-dose budesonide increases the probability of well 
controlled asthma compared to a substantial increase in the 
dose of ICS.
The OPTIMA trial was a double-blind, randomized, and 
parallel-group study designed to determine whether regular 
treatment with low doses of inhaled budesonide, with or 
without doses of inhaled formoterol, would reduce severe 
asthma exacerbations and improve asthma control. In one 
arm of the trial, patients aged 12 years and older who were 
already taking budesonide at baseline were randomized 
to receive: 1) budesonide 100 µg bid, 2) budesonide/
formoterol 100 µg/4.5 µg bid, 3) budesonide 200 µg bid, 
or 4) budesonide/formoterol 200 µg/4.5 µg bid.55 The 
addition of formoterol reduced the risk for severe asthma 
exacerbations and improved asthma control more effectively 
than doubling the dose of budesonide.
Numerous other studies and meta-analysis of adults and 
children aged 12 years and older have established that the 
combination of ICS/LABA is more effective at controlling 
symptoms, improving lung function, and reducing asthma 
exacerbations than doubling the dose of ICS.56–59 How-
ever, there have been only a few studies of the efficacy of 
ICS/LABAs in asthmatics less than 12 years old, and to 
the best of our knowledge, none in children aged less than 
five years.
Tal and colleagues evaluated the effect on lung function 
and tolerability of budesonide/formoterol in a single inhaler 
in children (mean age 11 years) with moderate to persistent 
asthma.60 This was a 12-week, double-blind, parallel-group, 
multicenter trial that randomized 286 asthmatic children to 
either budesonide/formoterol 90/9 µg bid or budesonide 
200 µg bid. Children who received combination budesonide/
formoterol had increased morning peak expiratory flow 
(PEF) relative to baseline compared to budesonide alone 
(7.22% predicted normal versus 3.45% predicted normal, 
respectively). Evening PEF also increased significantly 
with budesonide/formoterol compared to budesonide alone 
(6.13% predicted normal versus 2.73% predicted normal, 
respectively). Mean FEV1 and serial FEV1 measured over 
12 hours increased significantly with budesonide/formoterol 
compared to budesonide alone. Combination budesonide/
formoterol in a single inhaler provided rapid improvements 
in PEF and FEV1 compared to inhaled budesonide alone. 
The two treatment groups were similar in their adverse event 
profile and rates of discontinuation.
In a similar study by Pohunek and colleagues, investigators 
compared the efficacy and safety of combination therapy 
with budesonide and formoterol versus budesonide alone in 
children ages 4 to 11 years.61 In a 12-week, double-blind study, 
630 children were randomized to: 1) budesonide/formoterol 
90/9 µg bid, 2) budesonide 200 µg bid, and 3) budesonide 
(90 µg) + formoterol (9 µg) in separate inhalers. The budesonide/
formoterol combination significantly improved morning Therapeutics and Clinical Risk Management 2010:6 71
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PEF, evening PEF, and FEV1 compared with budesonide alone. 
There was no significant difference between the budesonide/
formoterol and budesonide + formoterol in separate inhalers. 
The adverse event profiles were similar in all groups and there 
were no serious asthma-related adverse events in any treat-
ment group. Combination budesonide/formoterol significantly 
improved lung function in children aged 4 to 11 years with 
asthma compared to budesonide alone.
These studies, although small, suggest that budesonide/
formoterol combination is a safe and effective treatment 
option for children with asthma.
Salmeterol and formoterol are highly selective, third 
generation LABAs that have been available for use since the 
early 1990s. Salmeterol and formoterol, however, differ in 
their pharmacological properties. One important difference 
is that the onset of action of formoterol is faster than that of 
salmeterol.62,63 A significantly greater improvement in FEV1 
was noted within three minutes of dosing with formoterol 
than salmeterol and continued to have a more pronounced 
effect for the three hours following dosing. Formoterol 
produces bronchodilation as fast as the short-acting 
ß2-agonist salbutamol.64,65 In the Salmeterol Multicenter 
Asthma Research Trial, comparing daily treatment with 
salmeterol or placebo added to standard asthma therapy 
for adults resulted in an increased risk of asthma-related 
deaths in patients treated with salmeterol (13 deaths out of 
13,176 patients treated with salmeterol versus three deaths 
out of 13,179 patients treated with placebo).66 In addition, 
increased numbers of severe asthma exacerbations were 
noted in the trials submitted to the US Food and Drug 
Administration (FDA) for formoterol approval.67 The 
association with severe asthma exacerbations and asthma-
related deaths has resulted in a black box warning label on 
all preparations containing LABAs. A single nucleotide 
(Arg–Arg versus Gly–Gly) substitution in the β2-agonist 
receptor gene may be associated with worsening of asthma 
in this subset of patients taking salmeterol.68,69 It is worth 
noting that an increased risk of asthma-related deaths was 
not seen in the subset of patients reporting ICS use at base-
line. Likewise, the evidence for increased risk of severe 
exacerbations from LABAs may stem from studies that 
compared monotherapy with LABAs versus monotherapy 
with ICS.70,71 Although it is still unclear whether salmeterol 
in combination with ICS still results in worsening of asthma 
in patients with the Arg–Arg genotype, a recent large retro-
spective study showed no such association.72 LABA must 
never be used as monotherapy and should be always used 
in combination with ICS.
inhaled corticosteroid in combination 
with leukotriene receptor antagonists
Use of LTRAs as adjunctive therapy to ICS has not been 
studied well in children aged 5–11 years and has not been 
studied at all in children aged less than four years. The 
majority of studies have been done using adult subjects. 
LTRAs may be added when asthma is not controlled on 
ICS alone. Lofdahl and colleagues showed that addition 
of montelukast to beclomethasone significantly improved 
FEV1 in asthmatics aged 15 years and older.73 Furthermore, 
addition of LTRA to ICS may be an effective and well 
tolerated alternative to doubling the dose of ICS in patients 
with uncontrolled asthma. In the COMPACT study, adult 
asthmatics with inadequately controlled asthma showed 
similar improvements in symptoms, exacerbations, symptom-
free days, peripheral eosinophil counts, and asthma-specific 
quality of life when given a LTRA in addition to their current 
dose of ICS or had their ICS dose doubled.74 Finally addition 
of LTRAs to ICS may also allow reduction of ICS dose in 
asthmatics.75 In a double-blind, placebo-controlled study, 
26 adult patients with stable asthma on ICS were randomized 
to montelukast or placebo for up to 12 weeks. Compared to 
placebo, montelukast allowed significant reduction in the 
ICS dose. LTRAs may be used as monotherapy in patients 
with mild asthma (step 2 in NAEPP ERP 3 and 2006 GINA) 
although ICS are often the preferred choice.1,2
Currently most asthma guidelines recommend addition of 
LABA versus LTRA to ICS as the preferred strategy in most 
age groups of children with asthma. While several studies 
have compared LABA versus LTRA addition to ICS in terms 
of efficacy, a detailed discussion is beyond the scope of this 
review, and may be found elsewhere.76–78
New paradigm: combination 
therapy as maintenance and reliever
Periodic fluctuations in symptoms and airway inflammation 
are characteristic of asthma and treatment requirements can 
vary over time. Reliever medications such as short-acting 
β2-agonist provide rapid bronchodilation and symptom relief 
but do not treat the underlying inflammatory process. O’Byrne 
and colleagues challenged the treatment paradigm of fixed 
dosing of ICS/LABA and proposed that combination therapy 
could be used as both maintenance and reliever therapy.79 In 
this pivotal study, the use of the combination of a rapid LABA 
(formoterol) and an inhaled glucocorticosteroid (budesonide) 
in a single inhaler both as a controller and reliever was effec-
tive in maintaining high levels of asthma control. This was Therapeutics and Clinical Risk Management 2010:6 72
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a double-blind, parallel-group study where 2,760 patients 
aged 4 to 80 years were randomized to receive either: 
1) budesonide/formoterol 80/4.5 µg bid as maintenance 
therapy plus budesonide/formoterol 80/4.5 µg as needed 
for reliever therapy, 2) budesonide/formoterol 80/4.5 µg 
bid as maintenance plus terbutaline 0.4 mg as reliever, or 
3) budesonide 320 µg bid as maintenance plus terbutaline 
0.4 mg as reliever. The patients who took budesonide/
formoterol as both maintenance and reliever therapy had a 
reduced risk of severe asthma exacerbations, need for sys-
temic steroids, improved asthma symptoms and improved 
lung function compared with the traditional fixed-dosing 
regimens. More importantly, the average daily dose of ICS 
received per patient was lower in the budesonide/formoterol 
groups and all of the medications were well tolerated.
Rabe and colleagues demonstrated that the combination 
budesonide/formoterol used for both maintenance and 
reliever improved asthma control with a lower steroid dose 
compared with higher doses of budesonide.80 697 patients 
aged 12 years and older were randomized to receive either 
budesonide/formoterol 80/4.5 µg bid as maintenance therapy 
plus budesonide/formoterol 80/4.5 µg as needed for reliever 
therapy or budesonide 160 µg bid as maintenance therapy 
plus terbutaline 0.4 mg as needed for reliever therapy. 
Patients receiving the budesonide/formoterol combination 
for both maintenance and relief had greater lung function, 
decreased risk of exacerbations, fewer hospitalizations, 
and decreased asthma symptoms. The increased efficacy 
of budesonide/formoterol was achieved with less ICS than 
was used in the budesonide group (mean dose, 240 µg/day 
versus 498 µg/day) and with 77% fewer oral steroid treatment 
days versus budesonide alone (114 days versus 498 days, 
respectively).
In the Symbicort Maintenance and Reliever Therapy 
(SMART) trial, the combination therapy with budesonide 
and formoterol used both as maintenance and rescue was 
shown to be an effective and well tolerated treatment 
approach for pediatric asthma management.81 This was 
a prospective study involving 41 centers in 12 countries. 
341 children aged 4–11 years with uncontrolled asthma 
on current ICS therapy were randomized to receive either 
fixed-dose budesonide, fixed-dose combination budesonide/
formoterol or budesonide/formoterol maintenance and as 
needed therapy (SMART group). Children receiving the 
SMART regimen had reduced asthma exacerbations, reduced 
nocturnal symptoms, and improved lung function. 14% of 
patients receiving the SMART regimen had an exacerbation, 
compared to 38% and 26% of patients in the fixed-dose 
combination and fixed-dose budesonide groups, respectively. 
Time to first exacerbation was significantly longer in the 
SMART group compared to fixed-dose combination and 
fixed-dose budesonide groups, respectively. This benefit 
was attained while using less than half the daily dose of 
budesonide compared with the fixed-dose budesonide group. 
In addition, yearly growth was higher by 1 cm for children 
in the budesonide/formoterol group versus those on higher 
fixed-dose daily budesonide. This approach to asthma 
management is currently not guideline based therapy but 
may provide a better alternative to improving control and 
decreasing risk. The benefit in preventing exacerbations and 
improving asthma control appears to be a consequence of 
early intervention and providing additional anti-inflammatory 
therapy and rapid symptom relief. The timing of the increased 
steroid dose in close proximity to asthma worsening may 
be the key to the effectiveness of this strategy, although 
other studies have shown that increasing the ICS dosing 
during an acute attack may not reduce risk of asthma related 
morbidity.82–84
The unique pharmacological properties of budesonide/
formoterol in a single inhaler make it suitable for both 
maintenance dosing and as reliever therapy. Whether this 
approach can be employed with other combinations of 
controller and reliever requires further study. Currently, the 
budesonide/formoterol single combination inhaler is not 
licensed by the US FDA for use as reliever therapy for the 
treatment of asthma. However, the 2006 GINA guidelines 
do recommend that if a combination inhaler containing 
formoterol and budesonide is selected, it may be used for 
both rescue and maintenance therapy.2
Finally, adherence to therapy is an important factor in 
the success of asthma treatment. Patients often link their 
poor adherence to prescribed ICS therapy to the lack of an 
immediate effect, unlike the rapid onset of effect experienced 
with short-acting β2-agonist.85 Budesonide/formoterol main-
tenance and rescue therapy may provide a significant benefit 
for patients for whom adherence to two separate drugs may 
present serious difficulties or confusion.
Summary
Current asthma guidelines recommend treatment of asthma in 
children towards achieving and maintaining asthma control 
in order to reduce impairment due to asthma symptoms and 
to reduce risk of future asthma exacerbations. This approach 
likely reduces morbidity and mortality associated with 
uncontrolled asthma. Newer combination agents such as 
budesonide and fomoterol have been shown to be safe and Therapeutics and Clinical Risk Management 2010:6 73
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effective in treatment of asthma in children. Use of long-term 
controller agents like this in combination with improved 
compliance and treatment of co-morbid conditions have been 
successful in this endeavor. Early studies even suggest that 
this combination can be used to reduce asthma exacerbations 
when used on a more intermittent basis in some patients. 
However, more studies have to be completed before this 
strategy can be universally recommended.
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